Discovering
new biomarkers
for Women’s Health.

Who we are

In MiMARK, we care for Women’s Health. We are specialized in the discovery, verification and validation of biomarkers to develop new solutions for gynecological patients.

Our commited team

Antonio Gil,
PhD MD
Clinical lead

Eva Coll
Technical lead

Eva Colás,
PhD
Scientific lead

Marina Rigau, PhD, MBA
Business &
Financials

Mimark
ongoing project

The next step for diagnosing
endometrial cancer

Unmet clinical need

Abnormal vaginal bleeding affects 9M women in EU and US yearly. Diagnosis of endometrial cancer is mandatory since 10% of these women will suffer it. Current diagnosis is based on the pathological examination of an endometrial biopsy (pipelle biopsy), but this fails to diagnose 22% of patients, and provides an inaccurate diagnosis in 55% of cases. This failure is associated to the scarce cellularity of the sample. In those cases, invasive diagnosis using histeroscopy needs to be performed.

ENDOMETRIAL CANCER
4th
most common cancer
6th
most deathly cancer

IVD test based on the assessment of 5 protein biomarkers in the uterine fluid

Solution

WomEC is an in vitro diagnostic tool based on the determination of 5 protein biomarkers in uterine fluid samples to provide diagnosis to 100% of patients, rule out endometrial cancer with great specificity, and provide information on histological subtype of the tumor to guide surgical treatment.

WomEC is now being developed as an easy, quick and less costly diagnostic kit to facilitate the clinical implementation in clinical laboratories.

OUTCOMESIMPACT
Two patents filed in 2016 and 2017,
now extended in AU, BR, CA, US, EU, JP, CH
Well protected asset
4 clinical retrospective studies in 291 patients
using LC-PRM technology and ELISA technology
Proven accuracy in a clinical setting
International publications:
Oncotarget 2016, Clin Ca Research 2017, Expert Rev Proteomics. 2018
Credibility
Antibody tests achieved for 6 protein biomarkersPrototype feasibility
Validation of the clinical need +50 interviewsClinical relevance

We seek partners to foster
the WomEC development

Help us in our research

Call for gynecologists & pathologists!

We need you to fulfill this survey to help us understand the diagnostic process of endometrial cancer. Would WomEC have an added value on your diagnosis?

fill the survey here

Key Opinion Leaders are supporting WomEC

“WomEC will revolutionize uterine cancer diagnosis in the world”

Javier F. Magrina,
Director Gynecologic Oncology

“WomEC may lead to significant advances that impact the standard of care in the management of endometrial cancer”

Pedro T Ramirez,
Director of Minimally Invasive Surgical Res & Edu

“From a clinical perspective, the project is expected to benefit the European community”

Frederic Amant,
Head of the gynecology oncology department,
ex-chairman of the ENITEC consortium

Contact us

    Please, thick to consent to your data being stored in line with our privacy policy

    Funding sources

    Partners